UniProtKB/Swiss-Prot P54840: Variant p.Met363Val

Glycogen [starch] synthase, liver
Gene: GYS2
Feedback?

Variant information Variant position:

363 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Methionine (M) to Valine (V) at position 363 (M363V, p.Met363Val). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs2306180 [ dbSNP | Ensembl ]

Sequence information Variant position:

363 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

703 The length of the canonical sequence.
Location on the sequence:

LESLSRLNFLLRMHKSDITV M VFFIMPAKTNNFNVETLKGQ The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         LESLSRLNFLLRMHKSDITVMVFFIMPAKTNNFNVETLKGQ

Mouse                         LESLSRLNFLLRMHKSNVTVVVFFIMPAKTNNFNVETLKGQ

Rat                           LESLSRLNFLLRMHKSNVTVVVFFIMPAKTNNFNVETLKGQ

Baker's yeast                 IEALARLNYRLKVSGSKKTVVAFIVMPAKNNSFTVEALKGQ

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 703	Glycogen [starch] synthase, liver

Literature citations
Primary structure of human liver glycogen synthase deduced by cDNA cloning.
Nuttall F.Q.; Gannon M.C.; Bai G.; Lee E.Y.;
Arch. Biochem. Biophys. 311:443-449(1994)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; VARIANT VAL-363; Mutations in the liver glycogen synthase gene in children with hypoglycemia due to glycogen storage disease type 0.
Orho M.; Bosshard N.U.; Buist N.R.M.; Gitzelmann R.; Aynsley-Green A.; Blumel P.; Gannon M.C.; Nuttall F.Q.; Groop L.C.;
J. Clin. Invest. 102:507-515(1998)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; FUNCTION; CATALYTIC ACTIVITY; PATHWAY; VARIANTS GSD0 SER-39; PRO-339; VAL-363; ASP-446; GLN-479; PRO-483 AND ARG-491; CHARACTERIZATION OF VARIANTS GSD0 SER-39; PRO-339; VAL-363; ASP-446; GLN-479; PRO-483 AND ARG-491; Human liver glycogen synthase cDNA.
Nakabayashi H.; Nakayama T.;
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; VARIANT VAL-363; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]; VARIANT VAL-363;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.